Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients

Research output: Contribution to journalJournal articleResearchpeer-review

R. Nielsen, Henrik Wiggers, Mads Halbirk, H Bøtker, Jens Juul Holst, Ole Schmitz, Egon Randa Frandsen, S Nielsen, N Møller, Helene Nørrelund

We studied the metabolic effects of 48-h GLP-1 treatment in insulin resistant heart failure patients.In a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic HF patients with IHD received 48-h GLP-1 and placebo-infusion. We applied OGTT, hyperinsulinemic clamp, indirect calorimetry, forearm, and tracer methods.7 insulin resistant HF (EF 28%±2) patients completed the protocol. GLP-1 decreased plasma glucose levels (p=0.048) and improved glucose tolerance. 4 patients had hypoglycemic events during GLP-1 vs. none during placebo. GLP-1 treatment tended to increase whole body protein turnover (p=0.08) but did not cause muscle wasting. No significant changes in circulating levels of insulin, glucagon, free fatty acids or insulin sensitivity were detected.GLP-1 treatment decreased glucose levels and increased glucose tolerance in insulin resistant HF patients with IHD. Hypoglycemia was common and may limit the use of GLP-1 in these patients. Insulin sensitivity, lipid-, and protein metabolism remained unchanged.Data were collected at the examinational laboratories of Department of Endocrinology and Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Original languageEnglish
JournalExperimental and Clinical Endocrinology and Diabetes
Issue number5
Pages (from-to)266-72
Number of pages7
Publication statusPublished - 2012

ID: 38431407